# Neil Barman

> Neil Barman is a physician-executive and the Chief Executive Officer of Sound Blade Medical, a Halifax-based startup building handheld histotripsy devices that use focused ultrasound to liquify tissue without heat or incisions. A Stanford- and Northwestern-trained M.D., he has spent more than two decades turning early medical-device science into approved therapies, including a pivotal role in the first FDA approval of ultrasound renal denervation at ReCor Medical and early roles at companies later acquired by Medtronic and Stryker. He stepped up from COO to CEO at Sound Blade in July 2025 to steer its non-invasive surgery platform through clinical development.

- **Role:** Chief Executive Officer at Sound Blade Medical Inc.
- **Organizations:** Sound Blade Medical Inc., ReCor Medical, May Health, Ardian, Concentric Medical, Radiant Medical
- **Nationality:** American
- **Education:** B.S. in Biology, Phi Beta Kappa, Stanford University, M.D., Northwestern University Medical School, Management coursework, Kellogg School of Management (coursework during medical school)
- **Known for:** Helped secure the first FDA approval for ultrasound renal denervation therapy as CSO of ReCor Medical., Led the clinical/medical team at Concentric Medical that developed the first FDA-approved line of embolectomy catheters for ischemic stroke., Early senior team member at Ardian, acquired by Medtronic in 2011.

## Career timeline

- **early career** — Began medical-device career at Radiant Medical, investigating catheter-based cooling for heart attack and stroke.
- **2000s** — Led the clinical/medical team at Concentric Medical that developed the first FDA-approved line of embolectomy catheters for ischemic stroke.
- **2011** — Was an early employee and part of the senior management team at Ardian, which pioneered catheter-based renal denervation and was acquired by Medtronic in January 2011.
- **later** — Served as Chief Scientific Officer at ReCor Medical, helping secure the first FDA approval for ultrasound renal denervation therapy.
- **later** — Co-founded May Health, developing novel treatments for PCOS-related infertility.
- **2025** — Served as Chief Operating Officer of Sound Blade Medical, then appointed Chief Executive Officer on July 31, 2025.

## Achievements

- Helped secure the first FDA approval for ultrasound renal denervation therapy as CSO of ReCor Medical.
- Led the clinical/medical team at Concentric Medical that developed the first FDA-approved line of embolectomy catheters for ischemic stroke.
- Early senior team member at Ardian, acquired by Medtronic in 2011.
- Co-founded May Health, focused on PCOS-related infertility.
- Graduated Phi Beta Kappa with a B.S. in Biology from Stanford University.
- Promoted from COO to CEO of Sound Blade Medical in July 2025.

## Latest updates

- **2025-07** — Appointed Chief Executive Officer of Sound Blade Medical, succeeding into the role from Chief Operating Officer.
- **2025-01** — Sound Blade Medical raised US$16.5M (C$23.8M) Series A funding.

## Links

- Website: https://soundblademedical.com
- LinkedIn: https://www.linkedin.com/in/neilcbarman/

---

Profile page: https://yespress.io/neil-barman
Published by YesPress — https://yespress.io
Last updated: 2026-06-10